Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
By A. Sanyal, N. Chalasani, Kris V. Kowdley, A. McCullough, A. Diehl, N. Bass, B. Neuschwander‐Tetri, J. Lavine, J. Tonascia, A. Unalp and 6 more. New England Journal of Medicine, 2010
3,032 citations recorded by the source corpus.
BACKGROUND Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease. METHODS We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks. The primary outcome was an improvement in histologic features of nonalcoholic steatohepatitis, as assessed with the use of a composite of standardized scores for steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis. Given the two planned primary comparisons, P values of less than 0.025 were considered to indicate statistical significance. RESULTS Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P = 0.04). Serum alanine and aspartate aminotransferase levels were reduced with vitamin E and with pioglitazone, as compared with placebo (P<0.001 for both comparisons), and both agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for vitamin E and P = 0.12 for pioglitazone). Subjects who received pioglitazone gained more weight than did those who received vitamin E or placebo; the rates of other side effects were similar among the three groups. CONCLUSIONS Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes. There was no benefit of pioglitazone over placebo for the primary outcome; however, significant benefits of pioglitazone were observed for some of the secondary outcomes. (ClinicalTrials.gov number, NCT00063622.)
Subfields: Epidemiology, Hepatology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/08a0496e771f6b485427d5d76edc62fa548e58ae
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
In Pharmacology
Citations in the corpus
- Metabolism Disrupting Chemicals and Metabolic Disorders (2016, neutral): “alanine aminotransferase) may be insensitive for the detection of environmental liver disease[549] Novel biomarkers for fatty liver disease and fibrosis [550] are being developed for clinical use, and perhaps these could be applied to future environmental epidemiology studies.”
- Non-Alcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases (2017, neutral): “Nonetheless, pioglitazone did improve several discrete metrics of hepatic inflammation (Sanyal et al., 2010).”
- Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2015, result): “Placebo-treated groups in clinical trials of NASH have shown that a significant minority of patients may lose the diagnostic changes of NASH.(23) Our study reproduced observations from cross-sectional studies that portal inflammation correlates significantly with advanced liver fibrosis.”
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “placebo).(122) Because this study consisted of two primary comparisons (pioglitazone vs.”
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease (2018, background): “, glitazones are associated with phenotypical weight gain [136] and obeticholic acid induced pruritus and elevated LDL-C [137], the latter a potential concern in patients already at risk for cardiovascular disease.”